Despite concerns about treatment-related immunosuppression, a report out of Spain suggests SARS-CoV-2 precautions can offset risk for patients with diffuse large B-cell lymphoma.
Adjuvant olaparib continued to show a strong efficacy benefit in patients with BRCA1/2 mutation–positive, HER2-negative high-risk breast cancer, according to 6-year data from the OlympiA…
Virginia G. Kaklamani, MD, DSc, discusses how effective elacestrant (Orserdu) is in CDK4/6 inhibitor-naive estrogen receptor-positive/HER2-negative metastatic breast cancer treatment.
Findings from the BOREAS study showed that navtemadlin as a monotherapy led to safety and efficacy in patients with myelofibrosis who were relapsed or refractory…
Real-world data suggest optimal CLL/SLL treatment sequencing involves targeted therapies, including covalent BTKis and BCL2 inhibitors, for better survival outcomes.
Progression-free survival was superior with first-line maintenance of palbociclib in HR-positive, HER2-positive metastatic breast cancer.
In the phase 2 SOLTI VALENTINE trial, patritumab deruxtecan with or without letrozole showed similar efficacy to multiagent chemotherapy in HR-positive, HER2-negative breast cancer with…
Progression-free survival was superior with first-line maintenance of palbociclib in HR-positive, HER2-positive metastatic breast cancer.
Progression-free survival was superior with first-line maintenance of palbociclib in HR-positive, HER2-positive metastatic breast cancer.
Arlocabtagene autoleucel led to antitumor activity and an acceptable safety profile in heavily pretreated relapsed/refractory multiple myeloma, according to updated phase 1 trial data.
Lisaftoclax, a BCL-2 inhibitor, demonstrated efficacy and tolerability in combination with pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma as well as amyloidosis.
